false2021-09-30Q30001612042--12-31A total of 6,046,356 warrants outstanding as of September 30, 2021 can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented. Similarly, a total of 5,527,218 warrants outstanding as of September 30, 2020 are also considered antidilutive for the periods presented and have not been included in the calculation. 0001612042 2021-01-01 2021-09-30 0001612042 2021-07-01 2021-09-30 0001612042 2020-07-01 2020-09-30 0001612042 2020-01-01 2020-09-30 0001612042 2020-01-01 2020-12-31 0001612042 2020-12-31 0001612042 2021-09-30 0001612042 2021-01-01 2021-03-31 0001612042 2019-12-31 0001612042 2020-09-30 0001612042 asnd:VisenPharmaceuticalsMember 2021-01-01 2021-09-30 0001612042 asnd:Warrant1Member 2021-01-01 2021-09-30 0001612042 ifrs-full:TopOfRangeMember 2021-01-01 2021-09-30 0001612042 ifrs-full:BottomOfRangeMember 2021-01-01 2021-09-30 0001612042 ifrs-full:RetainedEarningsMember 2021-01-01 2021-09-30 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-09-30 0001612042 asnd:OtherCollaborationPartnersMember 2021-01-01 2021-09-30 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-01-01 2021-09-30 0001612042 ifrs-full:SharePremiumMember 2021-01-01 2021-09-30 0001612042 ifrs-full:IssuedCapitalMember 2021-01-01 2021-09-30 0001612042 srt:NorthAmericaMember 2021-01-01 2021-09-30 0001612042 country:CN 2021-01-01 2021-09-30 0001612042 asnd:MarketingApprovalMember 2021-01-01 2021-09-30 0001612042 asnd:Warrant1Member 2021-01-01 2021-09-30 0001612042 asnd:VisenPharmaceuticalsMember 2021-07-01 2021-09-30 0001612042 asnd:OtherCollaborationPartnersMember 2021-07-01 2021-09-30 0001612042 srt:NorthAmericaMember 2021-07-01 2021-09-30 0001612042 country:CN 2021-07-01 2021-09-30 0001612042 asnd:Warrant1Member 2021-07-01 2021-09-30 0001612042 asnd:VisenPharmaceuticalsMember 2020-07-01 2020-09-30 0001612042 srt:NorthAmericaMember 2020-07-01 2020-09-30 0001612042 country:CN 2020-07-01 2020-09-30 0001612042 asnd:Warrant1Member 2020-07-01 2020-09-30 0001612042 ifrs-full:RetainedEarningsMember 2020-01-01 2020-09-30 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-01-01 2020-09-30 0001612042 asnd:VisenPharmaceuticalsMember 2020-01-01 2020-09-30 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-01-01 2020-09-30 0001612042 ifrs-full:SharePremiumMember 2020-01-01 2020-09-30 0001612042 ifrs-full:IssuedCapitalMember 2020-01-01 2020-09-30 0001612042 srt:NorthAmericaMember 2020-01-01 2020-09-30 0001612042 country:CN 2020-01-01 2020-09-30 0001612042 asnd:Warrant1Member 2020-01-01 2020-09-30 0001612042 asnd:Warrant1Member 2020-01-01 2020-09-30 0001612042 asnd:VisenPharmaceuticalsMember 2021-09-30 0001612042 asnd:Warrant1Member 2021-09-30 0001612042 ifrs-full:DiscountedCashFlowMember ifrs-full:NotLaterThanOneYearMember 2021-09-30 0001612042 ifrs-full:DiscountedCashFlowMember ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2021-09-30 0001612042 ifrs-full:DiscountedCashFlowMember ifrs-full:LaterThanFiveYearsMember 2021-09-30 0001612042 ifrs-full:DiscountedCashFlowMember 2021-09-30 0001612042 ifrs-full:GrossCarryingAmountMember 2021-09-30 0001612042 ifrs-full:BottomOfRangeMember 2021-09-30 0001612042 ifrs-full:TopOfRangeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UsTreasuryBillsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UsTreasuryBillsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UsGovernmentBondsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UsGovernmentBondsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CommercialPapersMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CommercialPapersMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CorporateBondsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CorporateBondsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:AgencyBondsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:AgencyBondsMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FixedInterestRateMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FixedInterestRateMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FloatingInterestRateMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FloatingInterestRateMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:ZeroCouponMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:ZeroCouponMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:PrimeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:PrimeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:HighGradeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:HighGradeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UpperMediumGradeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UpperMediumGradeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:LowerMediumGradeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:LowerMediumGradeMember 2021-09-30 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UsTreasuryBillsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UsTreasuryBillsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UsGovernmentBondsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UsGovernmentBondsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CommercialPapersMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CommercialPapersMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CorporateBondsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CorporateBondsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:AgencyBondsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:AgencyBondsMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FixedInterestRateMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FixedInterestRateMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FloatingInterestRateMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FloatingInterestRateMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:ZeroCouponMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:ZeroCouponMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:PrimeMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:PrimeMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:HighGradeMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:HighGradeMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UpperMediumGradeMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UpperMediumGradeMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:LowerMediumGradeMember 2020-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:LowerMediumGradeMember 2020-12-31 0001612042 asnd:VisenPharmaceuticalsMember 2021-01-08 0001612042 asnd:VisenSeriesBFinancingMember 2021-01-08 2021-01-08 0001612042 asnd:VisenPharmaceuticalsMember 2021-01-08 2021-01-08 0001612042 asnd:AmericanDepositorySharesMember asnd:PublicOfferingMember asnd:UnderwritersMember 2021-09-01 2021-09-01 0001612042 asnd:AmericanDepositorySharesMember asnd:PublicOfferingMember 2021-09-01 0001612042 asnd:AmericanDepositorySharesMember asnd:PublicOfferingMember asnd:UnderwritersMember 2021-09-01 0001612042 asnd:AmericanDepositorySharesMember asnd:PublicOfferingMember asnd:UnderwritersMember ifrs-full:TopOfRangeMember 2021-09-01 0001612042 asnd:AmericanDepositorySharesMember asnd:PublicOfferingMember asnd:UnderwritersMember 2021-09-02 2021-09-02 0001612042 asnd:AmericanDepositorySharesMember asnd:PublicOfferingMember 2021-09-07 2021-09-07 0001612042 asnd:Warrant1Member 2020-12-31 0001612042 ifrs-full:RetainedEarningsMember 2020-12-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-12-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001612042 ifrs-full:SharePremiumMember 2020-12-31 0001612042 ifrs-full:IssuedCapitalMember 2020-12-31 0001612042 ifrs-full:RetainedEarningsMember 2021-09-30 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-09-30 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-09-30 0001612042 ifrs-full:SharePremiumMember 2021-09-30 0001612042 ifrs-full:IssuedCapitalMember 2021-09-30 0001612042 ifrs-full:RetainedEarningsMember 2019-12-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2019-12-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2019-12-31 0001612042 ifrs-full:SharePremiumMember 2019-12-31 0001612042 ifrs-full:IssuedCapitalMember 2019-12-31 0001612042 ifrs-full:RetainedEarningsMember 2020-09-30 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-09-30 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-09-30 0001612042 ifrs-full:SharePremiumMember 2020-09-30 0001612042 ifrs-full:IssuedCapitalMember 2020-09-30 iso4217:EUR utr:Month iso4217:USD xbrli:shares xbrli:pure asnd:Segment iso4217:DKK xbrli:shares iso4217:EUR xbrli:shares iso4217:USD xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO
SECTION 13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of
November
,
2021 Commission File Number:
001-36815
(Exact Name of Registrant as Specified in Its Charter)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This report on Form
6-K
shall be deemed to be incorporated by reference into the registration statements on Form
S-8
(Registration Numbers
333-203040,
333-210810,
333-211512,
333-213412,
333-214843,
333-216883,
333-228576
and
333-254101)
and Form
F-3
(Registration Numbers
333-209336,
333-211511,
333-216882,
333-223134,
333-225284
and
333-256571)
of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Furnished as exhibits to this Report on Form
6-K
is information regarding the Company’s financial results for the fiscal quarter ended September 30, 2021.
|
|
|
|
|
|
|
|
99.1 |
|
|
|
|
99.2 |
|
|
|
|
101.INS |
|
XBRL Instance Document. |
|
|
101.SCH |
|
XBRL Taxonomy Extension Schema Document. |
|
|
101.CAL |
|
XBRL Taxonomy Extension Calculation Linkbase Document. |
|
|
101.DEF |
|
XBRL Taxonomy Extension Definition Linkbase Document. |
|
|
101.IAB |
|
XBRL Taxonomy Extension Labels Linkbase Document. |
|
|
101.PRE |
|
XBRL Taxonomy Extension Presentation Linkbase Document. |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: November 10, 2021 |
|
|
|
By: |
|
|
|
|
|
|
Michael Wolff Jensen |
|
|
|
|
Senior Vice President, Chief Legal Officer |
